TITLE

Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer

AUTHOR(S)
Li, Y; Starr, S E; Lisziewicz, J; Ho, W-Z
PUB. DATE
February 2000
SOURCE
Gene Therapy;Feb2000, Vol. 7 Issue 4, p321
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Among potential genetic targets for intervention in the HIV1 life cycle, the tat gene product is a key target. We investigated the ability of an antitat gene to inhibit HIV-1 activation and replication in chronically infected promonocyte (U1) and T cell (ACH-2) lines in vitro. U1 and ACH-2 cells were transduced with an antitat gene expressing RNA with dual (polymeric Tat activation response element and antisensetat) function that interferes with HIV-1 replication. Tumor necrosis factor-alpha (TNF-α) plus phorbol 12-myristate 13acetate (PMA)-induced HIV-1 expression, as determined by reverse transcribed PCR and reverse transcriptase (RT) assays, was significantly inhibited in U1 and ACH-2 cells transduced with the antitat gene, compared with the cells transduced with control vector and untransduced cells. This resistance to TNF-α plus PMA-induced HIV-1 expression was demonstrated in antitat gene-transduced U1 and ACH2 cells maintained in G418-free media for 5 months, suggesting that functional antitat gene may persist for many months in transduced cells and their progeny. Most importantly, we demonstrate that the antitat gene, when introduced into peripheral blood mononuclear cells (PBMC) isolated from patients with HIV-1 infection, inhibited TNF-α plus PMA-induced viral replication as determined by RTPCR and RT activity. In addition, the antitat gene enhanced the survival of CD4[sup +] T lymphocytes from such patients. These data suggest the feasibility of utilizing antitat gene therapy to block activation and replication of HIV-1 in latently infected monocytes and T-lymphocytes in vivo.
ACCESSION #
8852757

 

Related Articles

  • Safety Considerations Associated with Development and Clinical Application of Lentiviral Vector Systems for Gene Transfer. Buchschacher, Jr., Gary L. // Current Genomics;Jan2004, Vol. 5 Issue 1, p19 

    Lentiviral vector systems continue to be developed and investigated for possible use in clinical gene transfer studies and for application as potential gene therapies. These vector systems, as a new technology and potentially novel medical therapy, raise a number of safety concerns, both real...

  • RTE and CTE mRNA export elements synergistically increase expression of unstable, Rev-dependent HIV and SIV mRNAs. Smulevitch, Sergey; Bear, Jenifer; Alicea, Candido; Rosati, Margherita; Jalah, Rashmi; Zolotukhin, Andrei S.; Von Gegerfelt, Agneta; Michalowski, Daniel; Moroni, Christoph; Pavlakis, George N.; Felber, Barbara K. // Retrovirology;2006, Vol. 3, p6 

    Studies of retroviral mRNA export identified two distinct RNA export elements utilizing conserved eukaryotic mRNA export mechanism(s), namely the Constitutive Transport Element (CTE) and the RNA Transport Element (RTE). Although RTE and CTE are potent in nucleocytoplasmic mRNA transport and...

  • Immune Responses to Gene-Modified T Cells. Muul, Linda M.; Candotti, Fabio // Current Gene Therapy;Oct2007, Vol. 7 Issue 5, p361 

    Gene-modified T cells were the first gene therapy tool used in clinical gene transfer trials. After the first applications in immunodeficiency diseases, T cell gene therapy has been extended to HIV infection and cancer. The primary obstacle to successful T cell gene therapy has proven to be the...

  • Lentiviral vectors ready for prime-time. Kohn, Donald B. // Nature Biotechnology;Jan2007, Vol. 25 Issue 1, p65 

    The author comments on the paper presented on a clinical trial, in which an anti-HIV-1 gene is transferred and expressed using a lentiviral vector. The author suggests that the trial demonstrated safe gene delivery to patients' T-cells and that lentiviral vectors can be effectively used in...

  • A Transporter Gene (Sodium Iodide Symporter) for Dual Purposes in Gene Therapy: Imaging and Therapy. Je-Yoel Cho, N. // Current Gene Therapy;Dec2002, Vol. 2 Issue 4, p393 

    Radioiodide uptake (RAIU) in thyroid follicular epithelial cells, mediated by a plasma membrane transporter, sodium iodide symporter (NIS), provides a first step mechanism for thyroid cancer detection by radioiodide injection and effective radioiodide treatment for patients with invasive,...

  • Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Goula, D; Becker, N; Lemkine, G F; Normandie, P; Rodrigues, J; Mantero, S; Levi, G; Demeneix, B A // Gene Therapy;Mar2000, Vol. 7 Issue 6, p499 

    Intravenous administration could become a delivery route of choice for prophylactic and curative gene therapies on condition that genes cross the capillary barrier and reach target tissues without being degraded. We investigated the kinetics and process of transgene delivery through mouse lung...

  • HSV-1 VP22 augments adenoviral gene transfer to CNS neurons in the retina and striatum in vivo. Kretz, A.; Wybranietz, W.A.; Hermening, S.; Lauer, U.M.; Isenmann, S. // Molecular Therapy;May2003, Vol. 7 Issue 5, p659 

    One of the obstacles to efficient vector-mediated gene transfer to the CNS is limited transduction of target neurons. The VP22 tegument protein of HSV-1 can cross biological membranes and translocate the VP22 protein from primarily transfected cells to many surrounding cells in vitro. Here, we...

  • Gene transfer medicinal products.  // WHO Drug Information;2002, Vol. 16 Issue 4, p275 

    Cites efforts of the World Health Organization's Clinical Gene Transfer Monitoring Group to develop a general definition of gene transfer medicinal products. Brief history of gene therapy.

  • Antibody gene transfer for HIV immunoprophylaxis. Balazs, Alejandro B; West, Anthony P // Nature Immunology;Dec2012, Vol. 14 Issue 1, p1 

    Antibody gene transfer, which involves the delivery of genes that encode potent, broadly neutralizing antibodies to human immunodeficiency virus (HIV), is a promising new strategy for preventing HIV infection. A satellite symposium at the AIDS Vaccine 2012 conference brought together many of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics